Biobank of Samples From Patients With Infectious Diseases
NCT ID: NCT06722131
Last Updated: 2024-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
1000 participants
OBSERVATIONAL
2025-01-01
2031-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The population of the study will consist of patients treated in the Infectious Diseases Departments of Saint-Louis and Lariboisière Hospitals, with a diagnosis of infectious disease, and who have biological samples in the context of their routine medical care.
The diseases studied in this research project are bacterial infections (urinary tract infections, neurologic infections, sexually transmitted infections, pulmonary infections), viral infections (HIV, hepatitis, respiratory viruses, viruses affecting immunocompromised patients) and fungal infections (Aspergillus, Mucorales, Cryptococcus). These diseases are the domains of expertise and research of the clinical and biological teams at the Saint-Louis and Lariboisière hospitals.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients diagnosed with an infectious disease
Sampling
Additional biological sampling at the same time as routine-care samples taken in the context of the diagnosis of the infectious disease and if planned at one and 12 months of follow-up
* The considered samples are as follows :
* Blood sample tubes (5 x 5 mL tubes, i.e. 25 mL)
* Infection site sample if applicable :
* Urine (10 mL)
* Stool (1 mL)
* CSF (1 mL)
* Sputum (1 mL) or bronchoalveolar lavage fluid (10 mL)
* Nasopharyngeal swab (one swab)
* Genital swab (one swab)
* Skin swab (one swab)
* Biopsy (a fragment of a lung, kidney or brain biopsy, if performed)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sampling
Additional biological sampling at the same time as routine-care samples taken in the context of the diagnosis of the infectious disease and if planned at one and 12 months of follow-up
* The considered samples are as follows :
* Blood sample tubes (5 x 5 mL tubes, i.e. 25 mL)
* Infection site sample if applicable :
* Urine (10 mL)
* Stool (1 mL)
* CSF (1 mL)
* Sputum (1 mL) or bronchoalveolar lavage fluid (10 mL)
* Nasopharyngeal swab (one swab)
* Genital swab (one swab)
* Skin swab (one swab)
* Biopsy (a fragment of a lung, kidney or brain biopsy, if performed)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with one of the following infectious diseases :
* Infection with HIV-1 or HIV-2, or person at risk of infection with HIV
* Viral hepatitis (HAV, HBV, HCV, HDV, HEV)
* Pulmonary infections: bacterial (notably Nocardia), viral (Influenza, RSV, SARS-CoV-2, Adenovirus), fungal (Aspergillus, Mucorales)
* Urinary tract infections
* Sexually transmitted infections (Neisseria gonorrheae, Chlamydia trachomatis, Mycoplasma genitalium, Treponema pallidum)
* Neuromeningeal infections: (Neisseria meningitidis, Streptococcus pneumoniae), viral (HSV, VZV), fungal (Cryptococcus).
* Infections affecting immunocompromised patients: herpes viruses (HSV, VZV, CMV, EBV), polyomavirus BK
* Emerging pathogen X (in the event of an epidemic)
* Signature of research consent form
* Health coverage with social security system or state medical aid
Exclusion Criteria
* Inability to give consent (cognitive impairment etc...)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APHP240413
Identifier Type: -
Identifier Source: org_study_id